Mar, 2024.4 According to the CDE official website, Hengrui Pharmaceuticals’ clinical trial application for Class 1 new drug SHR-1139 injection has received implicit permission, and the indication is psoriasis.
Psoriasis is a complex autoimmune disorder characterized by chronic inflammation of the skin, influenced by environmental factors and controlled by multiple genetic components. With over 7 million reported cases in China alone, psoriasis has become a significant health concern. Projections suggest that by 2030, the psoriasis market in China will reach an estimated value of $9.5 billion, with a compound annual growth rate of 27.1%. The global incidence of psoriasis is also on the rise, emphasizing the urgent need for effective treatment options.
Biological drugs have gradually become one of the mainstream treatments for psoriasis currently, and related drugs mainly focus on targets such as TNF-α and IL family. Hengrui Pharmaceuticals has also deployed psoriasis treatment drugs, among which funakizumab injection (SHR-1314) targets the IL-17A target. SHR-1139 is another psoriasis drug from Hengrui Pharmaceuticals. It is a Class 1 therapeutic biological product and its target has not yet been disclosed.
After the clinical trial application of SHR-1139 for the treatment of psoriasis is approved, Hengrui Pharmaceuticals’ immune sector is expected to add another potentially blockbuster drug.
In addition to the immunology field, Hengrui Pharmaceuticals also has plans in anti-tumor, cardiovascular and metabolic, pain, infection, ophthalmology and other fields, with a focus on the anti-tumor segment. Since the beginning of this year, three products of Hengrui Pharmaceuticals have obtained fast-track qualifications from the US FDA.
By accelerating the clinical progress of pipelines under development, it is expected that Hengrui Pharmaceuticals can reap more innovative fruits in 2024.
